All In Biotech

Drug Trial Radar · NCT06544720

SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas

Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Aug 2, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.

Conditions

  • Human Papillomavirus Associated Carcinomas
  • Cervical Cancer
  • Head and Neck Cancers
  • Anal Cancer
  • Vulva Cancer
  • Vaginal Cancer
  • Penile Cancer
  • HPV-Related Malignancy

Interventions

  • SCG142 TCR-T cellsBiological

    Monotherapy of SCG142

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The affiliated hosptial of qingdao university

    Qingdao, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.